PDS Biotech's Cancer Drug Hits Key Trial Goal as Q2 Losses Widen to $9.4M - Stock Titan
5 weeks ago • Google News
PDS Biotechnology Corp (PDSB)
US$ 00%
Price Chart
Key Statistics
Market Cap
$ 55.49M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
0
52W High
$ 4.29
52W Low
$ 0.85
Dividend Yield
0.00%
Beta
1.15
Technicals
50-Day MA
1.1976
200-Day MA
1.4181
52 Week High
4.29
52 Week Low
0.8505
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in .
Employees
24
Headquarters
Princeton, NJ
CEO
Dr. Frank K. Bedu-Addo Ph.D.